{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T04:39:58Z","timestamp":1773117598144,"version":"3.50.1"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"National Science Fund of China","award":["82271272"],"award-info":[{"award-number":["82271272"]}]},{"name":"Sichuan Science and Technology Program","award":["2023YFS0265"],"award-info":[{"award-number":["2023YFS0265"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Sci"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1007\/s10072-025-08763-x","type":"journal-article","created":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T02:09:36Z","timestamp":1767924576000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Elevated neurofilament light chain (NfL) in blood and CSF as a biomarker for Parkinson\u2019s disease cognitive impairment: A meta-analysis"],"prefix":"10.1007","volume":"47","author":[{"given":"Can","family":"Liu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yingqi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9971-6185","authenticated-orcid":false,"given":"Ruwei","family":"Ou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,1,9]]},"reference":[{"key":"8763_CR1","doi-asserted-by":"crossref","DOI":"10.1038\/nrdp.2017.13","volume":"3","author":"W Poewe","year":"2017","unstructured":"Poewe W et al (2017) Parkinson disease. Nat Rev Dis Primers 3:17013","journal-title":"Nat Rev Dis Primers"},{"issue":"9996","key":"8763_CR2","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/S0140-6736(14)61393-3","volume":"386","author":"LV Kalia","year":"2015","unstructured":"Kalia LV, Lang AE (2015) Parkinson\u2019s disease. Lancet 386(9996):896\u2013912","journal-title":"Lancet"},{"key":"8763_CR3","doi-asserted-by":"crossref","unstructured":"Abdelnour C, et al., 2025 How to advance the pharmacological management of cognitive impairment in Parkinson's disease. J Parkinsons Dis p. 1877718x251315645.","DOI":"10.1177\/1877718X251315645"},{"key":"8763_CR4","doi-asserted-by":"publisher","DOI":"10.3390\/cells14020086","author":"MK Park","year":"2025","unstructured":"Park MK et al (2025) Modulation of second messenger signaling in the brain through PDE4 and PDE5 inhibition: therapeutic implications for neurological disorders. Cells. https:\/\/doi.org\/10.3390\/cells14020086","journal-title":"Cells"},{"issue":"1","key":"8763_CR5","doi-asserted-by":"crossref","DOI":"10.1111\/ene.70022","volume":"32","author":"K Yoshimura","year":"2025","unstructured":"Yoshimura K et al (2025) Neural substrates underlying distinct dual cognitive syndromes in Parkinson\u2019s disease. Eur J Neurol 32(1):e70022","journal-title":"Eur J Neurol"},{"issue":"10","key":"8763_CR6","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1016\/j.autrev.2016.07.022","volume":"15","author":"A De Virgilio","year":"2016","unstructured":"De Virgilio A et al (2016) Parkinson\u2019s disease: autoimmunity and neuroinflammation. Autoimmun Rev 15(10):1005\u20131011","journal-title":"Autoimmun Rev"},{"issue":"2","key":"8763_CR7","doi-asserted-by":"crossref","DOI":"10.3390\/cells14020140","volume":"14","author":"AD Mooradian","year":"2025","unstructured":"Mooradian AD, Haas MJ (2025) Role of thyroid hormone in neurodegenerative disorders of older people. Cells 14(2):140","journal-title":"Cells"},{"issue":"4","key":"8763_CR8","volume":"102","author":"KAQ Cousins","year":"2024","unstructured":"Cousins KAQ et al (2024) Evaluation of ATN(PD) framework and biofluid markers to predict cognitive decline in early Parkinson disease. Neurology 102(4):e208033","journal-title":"Neurology"},{"issue":"12","key":"8763_CR9","volume":"17","author":"Y Liu","year":"2024","unstructured":"Liu Y et al (2024) Longitudinal correlation of cerebrospinal fluid GFAP and the progression of cognition decline in different clinical subtypes of Parkinson\u2019s disease. Clin Transl Sci 17(12):e70111","journal-title":"Clin Transl Sci"},{"issue":"3","key":"8763_CR10","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1007\/s13760-023-02441-5","volume":"124","author":"YY Peng","year":"2024","unstructured":"Peng YY et al (2024) Serum level of YWHAG as a diagnostic marker of cognitive impairment in Parkinson\u2019s disease patients. Acta Neurol Belg 124(3):879\u2013885","journal-title":"Acta Neurol Belg"},{"issue":"12","key":"8763_CR11","doi-asserted-by":"crossref","first-page":"2945","DOI":"10.1002\/mds.28779","volume":"36","author":"WW Aamodt","year":"2021","unstructured":"Aamodt WW et al (2021) Neurofilament light chain as a biomarker for cognitive decline in Parkinson disease. Mov Disord 36(12):2945\u20132950","journal-title":"Mov Disord"},{"key":"8763_CR12","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.parkreldis.2021.07.028","volume":"90","author":"L Niemann","year":"2021","unstructured":"Niemann L et al (2021) Serum neurofilament is associated with motor function, cognitive decline and subclinical cardiac damage in advanced Parkinson\u2019s disease (MARK-PD). Parkinsonism Relat Disord 90:44\u201348","journal-title":"Parkinsonism Relat Disord"},{"issue":"1","key":"8763_CR13","doi-asserted-by":"crossref","DOI":"10.1038\/s41531-022-00384-x","volume":"8","author":"L Batzu","year":"2022","unstructured":"Batzu L et al (2022) Plasma p-tau181, neurofilament light chain and association with cognition in Parkinson\u2019s disease. NPJ Parkinsons Dis 8(1):154","journal-title":"NPJ Parkinsons Dis"},{"issue":"9","key":"8763_CR14","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s10654-010-9491-z","volume":"25","author":"A Stang","year":"2010","unstructured":"Stang A (2010) Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol 25(9):603\u2013605","journal-title":"Eur J Epidemiol"},{"issue":"1","key":"8763_CR15","doi-asserted-by":"crossref","first-page":"35","DOI":"10.5093\/ejpalc2018a5","volume":"10","author":"JF Salgado","year":"2018","unstructured":"Salgado JF (2018) Transforming the area under the normal curve (AUC) into Cohen\u2019s d, Pearson\u2019s rpb, odds-ratio, and natural log odds-ratio: two conversion tables. Eur J Psychol Appl Leg Context 10(1):35\u201347","journal-title":"Eur J Psychol Appl Leg Context"},{"key":"8763_CR16","volume":"364","author":"MH Murad","year":"2019","unstructured":"Murad MH et al (2019) When continuous outcomes are measured using different scales: guide for meta-analysis and interpretation. BMJ 364:k4817","journal-title":"BMJ"},{"issue":"11","key":"8763_CR17","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1001\/archneurol.2012.1654","volume":"69","author":"S Hall","year":"2012","unstructured":"Hall S et al (2012) Accuracy of a panel of 5 cerebrospinal fluid biomarkers in the differential diagnosis of patients with dementia and\/or parkinsonian disorders. Arch Neurol 69(11):1445\u20131452","journal-title":"Arch Neurol"},{"key":"8763_CR18","first-page":"8","volume":"358","author":"YY Zhu","year":"2021","unstructured":"Zhu YY et al (2021) Association between plasma neurofilament light chain levels and cognitive function in patients with Parkinson\u2019s disease. J Neuroimmunol 358:8","journal-title":"J Neuroimmunol"},{"issue":"3","key":"8763_CR19","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1001\/jamaneurol.2018.3746","volume":"76","author":"B Olsson","year":"2019","unstructured":"Olsson B et al (2019) Association of cerebrospinal fluid neurofilament light protein levels with cognition in patients with dementia, motor neuron disease, and movement disorders. JAMA Neurol 76(3):318\u2013325","journal-title":"JAMA Neurol"},{"key":"8763_CR20","volume":"1805","author":"S Mao","year":"2023","unstructured":"Mao S et al (2023) Association of serum neurofilament light chain and glial fibrillary acidic protein levels with cognitive decline in Parkinson\u2019s disease. Brain Res 1805:148271","journal-title":"Brain Res"},{"issue":"11","key":"8763_CR21","doi-asserted-by":"crossref","first-page":"5461","DOI":"10.1007\/s00415-023-11875-z","volume":"270","author":"Y Mizutani","year":"2023","unstructured":"Mizutani Y et al (2023) Associations of Alzheimer\u2019s-related plasma biomarkers with cognitive decline in Parkinson\u2019s disease. J Neurol 270(11):5461\u20135474","journal-title":"J Neurol"},{"key":"8763_CR22","doi-asserted-by":"crossref","DOI":"10.1016\/j.neulet.2023.137219","volume":"804","author":"L Dong","year":"2023","unstructured":"Dong L et al (2023) Associations of blood UCH-L1 and NfL levels with cognitive dysfunction in Parkinson\u2019s disease patients. Neurosci Lett 804:137219","journal-title":"Neurosci Lett"},{"key":"8763_CR23","volume":"14","author":"ZH Sheng","year":"2022","unstructured":"Sheng ZH et al (2022) Cerebrospinal fluid neurofilament dynamic profiles predict cognitive progression in individuals with de novo Parkinson\u2019s disease. Front Aging Neurosci 14:1061096","journal-title":"Front Aging Neurosci"},{"issue":"10","key":"8763_CR24","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1001\/jamaneurol.2015.1449","volume":"72","author":"DC B\u00e4ckstr\u00f6m","year":"2015","unstructured":"B\u00e4ckstr\u00f6m DC et al (2015) Cerebrospinal fluid patterns and the risk of future dementia in early, incident Parkinson disease. JAMA Neurol 72(10):1175\u20131182","journal-title":"JAMA Neurol"},{"key":"8763_CR25","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.parkreldis.2022.05.020","volume":"105","author":"J Pagonabarraga","year":"2022","unstructured":"Pagonabarraga J et al (2022) Dissociable contribution of plasma NfL and p-tau181 to cognitive impairment in Parkinson\u2019s disease. Parkinsonism Relat Disord 105:132\u2013138","journal-title":"Parkinsonism Relat Disord"},{"issue":"1","key":"8763_CR26","doi-asserted-by":"crossref","first-page":"77","DOI":"10.3233\/JPD-191766","volume":"10","author":"CH Chen","year":"2020","unstructured":"Chen CH, Lee BC, Lin CH (2020) Integrated plasma and neuroimaging biomarkers associated with motor and cognition severity in Parkinson\u2019s disease. J Parkinsons Dis 10(1):77\u201388","journal-title":"J Parkinsons Dis"},{"key":"8763_CR27","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1038\/s41598-017-18329-3","volume":"8","author":"YS Lin","year":"2018","unstructured":"Lin YS et al (2018) Levels of plasma neurofilament light chain and cognitive function in patients with Alzheimer or Parkinson disease. Sci Rep 8:8","journal-title":"Sci Rep"},{"issue":"1","key":"8763_CR28","doi-asserted-by":"crossref","DOI":"10.1038\/s41531-023-00447-7","volume":"9","author":"Y Tang","year":"2023","unstructured":"Tang Y et al (2023) Plasma GFAP in Parkinson\u2019s disease with cognitive impairment and its potential to predict conversion to dementia. NPJ Parkinsons Dis 9(1):23","journal-title":"NPJ Parkinsons Dis"},{"key":"8763_CR29","volume":"16","author":"L Gu","year":"2024","unstructured":"Gu L et al (2024) Predictive value of serum neurofilament light chain for cognitive impairment in Parkinson\u2019s disease. Front Aging Neurosci 16:1465016","journal-title":"Front Aging Neurosci"},{"issue":"1","key":"8763_CR30","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s12883-022-02558-9","volume":"22","author":"Y Huang","year":"2022","unstructured":"Huang Y et al (2022) Serum NFL discriminates Parkinson disease from essential tremor and reflect motor and cognition severity. BMC Neurol 22(1):39","journal-title":"BMC Neurol"},{"issue":"1","key":"8763_CR31","doi-asserted-by":"crossref","first-page":"3400","DOI":"10.1038\/s41467-021-23620-z","volume":"12","author":"NJ Ashton","year":"2021","unstructured":"Ashton NJ et al (2021) A multicentre validation study of the diagnostic value of plasma neurofilament light. Nat Commun 12(1):3400","journal-title":"Nat Commun"},{"issue":"11","key":"8763_CR32","first-page":"e1104","volume":"93","author":"CH Lin","year":"2019","unstructured":"Lin CH et al (2019) Blood NfL: a biomarker for disease severity and progression in Parkinson disease. Neurology 93(11):e1104\u2013e1111","journal-title":"Neurology"},{"issue":"7","key":"8763_CR33","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1002\/mds.28056","volume":"35","author":"S Lerche","year":"2020","unstructured":"Lerche S et al (2020) CSF NFL in a longitudinally assessed PD cohort: age effects and cognitive trajectories. Mov Disord 35(7):1138\u20131144","journal-title":"Mov Disord"},{"key":"8763_CR34","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.jocn.2023.01.015","volume":"110","author":"F Nabizadeh","year":"2023","unstructured":"Nabizadeh F et al (2023) Serum neurofilament light chain in LRRK2 related Parkinson\u2019s disease: a five years follow-up. J Clin Neurosci 110:12\u201318","journal-title":"J Clin Neurosci"},{"key":"8763_CR35","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.parkreldis.2020.04.009","volume":"74","author":"F Sampedro","year":"2020","unstructured":"Sampedro F et al (2020) Serum neurofilament light chain levels reflect cortical neurodegeneration in de novo Parkinson\u2019s disease. Parkinsonism Relat Disord 74:43\u201349","journal-title":"Parkinsonism Relat Disord"},{"issue":"1","key":"8763_CR36","volume":"11","author":"MS Baek","year":"2021","unstructured":"Baek MS et al (2021) Temporal trajectory of biofluid markers in Parkinson\u2019s disease. Sci Rep 11(1):14820","journal-title":"Sci Rep"},{"issue":"1","key":"8763_CR37","volume":"9","author":"D Yang","year":"2023","unstructured":"Yang D et al (2023) Neurofilament light chain as a mediator between LRRK2 mutation and dementia in Parkinson\u2019s disease. NPJ Parkinsons Dis 9(1):132","journal-title":"NPJ Parkinsons Dis"},{"issue":"3","key":"8763_CR38","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1002\/alz.13560","volume":"20","author":"E Sanchez","year":"2024","unstructured":"Sanchez E et al (2024) Association of plasma biomarkers with cognition, cognitive decline, and daily function across and within neurodegenerative diseases: results from the Ontario Neurodegenerative Disease Research Initiative. Alzheimers Dement 20(3):1753\u20131770","journal-title":"Alzheimers Dement"},{"issue":"6","key":"8763_CR39","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1002\/mds.26578","volume":"31","author":"S Hall","year":"2016","unstructured":"Hall S et al (2016) Longitudinal measurements of cerebrospinal fluid biomarkers in Parkinson\u2019s disease. Mov Disord 31(6):898\u2013905","journal-title":"Mov Disord"},{"key":"8763_CR40","doi-asserted-by":"crossref","DOI":"10.1016\/j.nbd.2023.106237","volume":"185","author":"D Urso","year":"2023","unstructured":"Urso D et al (2023) Neurofilament light predicts worse nonmotor symptoms and depression in Parkinson\u2019s disease. Neurobiol Dis 185:106237","journal-title":"Neurobiol Dis"},{"issue":"12","key":"8763_CR41","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1007\/s00702-021-02423-y","volume":"128","author":"DG Park","year":"2021","unstructured":"Park DG et al (2021) Plasma neurofilament light chain level and orthostatic hypotension in early Parkinson\u2019s disease. J Neural Transm 128(12):1853\u20131861","journal-title":"J Neural Transm"},{"issue":"4","key":"8763_CR42","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1007\/s00415-023-12117-y","volume":"271","author":"R Ou","year":"2024","unstructured":"Ou R et al (2024) Relationship between plasma NFL and disease progression in Parkinson\u2019s disease: a prospective cohort study. J Neurol 271(4):1837\u20131843","journal-title":"J Neurol"},{"issue":"1","key":"8763_CR43","doi-asserted-by":"crossref","DOI":"10.1038\/s41531-024-00768-1","volume":"10","author":"CC Pedersen","year":"2024","unstructured":"Pedersen CC et al (2024) Serum neurofilament light at diagnosis: a prognostic indicator for accelerated disease progression in Parkinson\u2019s disease. NPJ Parkinsons Dis 10(1):162","journal-title":"NPJ Parkinsons Dis"},{"key":"8763_CR44","doi-asserted-by":"crossref","DOI":"10.1016\/j.jns.2025.123617","volume":"476","author":"M Campagnolo","year":"2025","unstructured":"Campagnolo M et al (2025) The role of blood-based biomarkers in Parkinsonian disorders, Alzheimer\u2019s disease and frontotemporal dementia. J Neurol Sci 476:123617","journal-title":"J Neurol Sci"},{"issue":"4","key":"8763_CR45","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1159\/000510325","volume":"49","author":"WC Lin","year":"2020","unstructured":"Lin WC et al (2020) Plasma total \u03b1-synuclein and neurofilament light chain: clinical validation for discriminating Parkinson\u2019s disease from normal control. Dement Geriatr Cogn Disord 49(4):401\u2013409","journal-title":"Dement Geriatr Cogn Disord"},{"issue":"6","key":"8763_CR46","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1213\/ANE.0000000000005773","volume":"133","author":"P Schober","year":"2021","unstructured":"Schober P, Mascha EJ, Vetter TR (2021) Statistics from a (agreement) to z (z score): a guide to interpreting common measures of association, agreement, diagnostic accuracy, effect size, heterogeneity, and reliability in medical research. Anesth Analg 133(6):1633\u20131641","journal-title":"Anesth Analg"},{"issue":"1","key":"8763_CR47","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1186\/s12888-021-03495-6","volume":"21","author":"X Jia","year":"2021","unstructured":"Jia X et al (2021) A comparison of the Mini-Mental State Examination (MMSE) with the Montreal Cognitive Assessment (MoCA) for mild cognitive impairment screening in Chinese middle-aged and older population: a cross-sectional study. BMC Psychiatry 21(1):485","journal-title":"BMC Psychiatry"},{"key":"8763_CR48","doi-asserted-by":"crossref","first-page":"448","DOI":"10.3389\/fneur.2020.00448","volume":"11","author":"HH Nielsen","year":"2020","unstructured":"Nielsen HH et al (2020) Acute neurofilament light chain plasma levels correlate with stroke severity and clinical outcome in ischemic stroke patients. Front Neurol 11:448","journal-title":"Front Neurol"},{"issue":"1","key":"8763_CR49","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1186\/s40001-023-01375-1","volume":"28","author":"P K\u00f6rtvelyessy","year":"2023","unstructured":"K\u00f6rtvelyessy P et al (2023) Serum neurofilament light chain in COVID-19 and the influence of renal function. Eur J Med Res 28(1):389","journal-title":"Eur J Med Res"}],"container-title":["Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-025-08763-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10072-025-08763-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-025-08763-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T16:03:51Z","timestamp":1773072231000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10072-025-08763-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":49,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["8763"],"URL":"https:\/\/doi.org\/10.1007\/s10072-025-08763-x","relation":{},"ISSN":["1590-1874","1590-3478"],"issn-type":[{"value":"1590-1874","type":"print"},{"value":"1590-3478","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"5 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The three authors report no disclosures relevant to the manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Financial disclosures"}},{"value":"The Ethics Committee of Sichuan University approved the study. The study was conducted in accordance with the Helsinki Declaration.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical standards"}},{"value":"The authors have no conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}],"article-number":"127"}}